Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
24
|
pubmed:dateCreated |
1993-1-26
|
pubmed:language |
nor
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0029-2001
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
112
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3122
|
pubmed:dateRevised |
2008-7-16
|
pubmed:meshHeading |
pubmed-meshheading:1281932-Agranulocytosis,
pubmed-meshheading:1281932-Drug Costs,
pubmed-meshheading:1281932-Drug Information Services,
pubmed-meshheading:1281932-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:1281932-Humans,
pubmed-meshheading:1281932-Neutropenia,
pubmed-meshheading:1281932-Norway
|
pubmed:year |
1992
|
pubmed:articleTitle |
[Recommendation to uncritical use of granulocyte colony-stimulating factor (G-CSF)?].
|
pubmed:publicationType |
Letter
|